Real-World Eligibility for FLAURA, FLAURA2, and MARIPOSA in Patients with EGFR-Mutated Advanced NSCLC: A Retrospective Single-Center Study
- 1Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan 20133, Italy
- 2Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Italy
Abstract
Introduction: First-line treatment options for EGFR-mutated NSCLC have expanded beyond osimertinib monotherapy following the FLAURA2 and MARIPOSA trials, which demonstrated improved long-term outcomes with combination strategies, albeit with increased toxicities. Given that randomized controlled trials (RCTs) typically enroll highly selected patients (pts), evaluating the representativeness of these cohorts in real-world (RW) practice is essential to inform RCT applicability. Methods: We retrospectively identified patients with EGFR-mutated advanced NSCLC treated with first-line osimertinib at Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, between January 2019 and August 2025. Clinical characteristics were collected, and eligibility for FLAURA, FLAURA2, and MARIPOSA was assessed according to the respective trial criteria. For survival analyses, patients were classified as trial-eligible or trial-ineligible according to FLAURA eligibility criteria, as all patients received first-line osimertinib. Results: Overall, 135 pts were included in the analysis; median age was 67 years (IQR 57–76), 17% had ECOG PS 2, and 11% harbored uncommon EGFR mutations. Only 31 patients (23%) met eligibility criteria for all three trials, whereas 91 (67%) were ineligible for all. The most frequent exclusion criteria included symptomatic CNS disease or spinal cord compression, ECOG PS 2, and EGFR mutation assessment by cytology or liquid biopsy. Both real-world progression free survival (rwPFS) and overall survival (OS) were numerically longer in trial-eligible than trial-ineligible patients (20.1 vs. 18.2 months and 29.9 vs. 22.3 months, respectively). Patients with negative prognostic characteristics such as ECOG PS ≥ 2, uncommon EGFR mutations, and liver metastases had significantly shorter OS, while other predefined risk factors showed only numerical trends. Conclusions: A substantial proportion of patients treated with first-line osimertinib in routine practice would not have met the eligibility criteria of pivotal EGFR-mutated NSCLC trials. Trial-ineligible patients had numerically shorter survival, likely reflecting adverse baseline characteristics. These findings highlight the limitations of direct extrapolation of RCT results to real-world populations.
Related
- Amivantamab plus chemotherapy vs. chemotherapy in participants with EGFR-mutant advanced non-small cell lung cancer after progression on osimertinib: a MARIPOSA-2 analysis of the Asian subgroup
- Efficacy and safety of third-generation EGFR-TKI rechallenge therapy in advanced non-small cell lung cancer patients with EGFR mutation: a retrospective cohort study
- BRAFV600E-Informed TI-RADS Reclassification of Biopsy Eligibility in Thyroid Nodules: A Retrospective Oracle Decision–Simulation Study
- Palliative Sedation at Home in Patients with Advanced Cancer: A Retrospective Observational Study of Clinical Characteristics and Sedation-Related Outcomes
- Anti-Obesity Medications Versus Metabolic Bariatric Surgery as Pathways to Heart Transplant Eligibility in LVAD-Supported Patients: A Narrative Review
BibTeX
@article{marchesi2026realworld,
title = {{Real-World Eligibility for FLAURA, FLAURA2, and MARIPOSA in Patients with EGFR-Mutated Advanced NSCLC: A Retrospective Single-Center Study}},
author = {Silvia Marchesi and Paolo Ambrosini and Chiara Cavalli and Rebecca Romanò and Alessia Vendittelli and Stefano Natangelo and Giuseppe Nardo and Margherita Piccinelli and Daniele Lorenzini and Marta Brambilla and Laura Mazzeo and Teresa Beninato and Giulia Corrao and Federica Perrone and Rosa Maria Di Mauro and Andra Diana Dumitrascu and Claudia Proto and Arsela Prelaj and Monica Ganzinelli and Filippo Guglielmo Maria De Braud and Giuseppe Lo Russo and Mario Occhipinti},
journal = {Cancers},
year = {2026},
month = oct,
doi = {10.3390/cancers18213480},
url = {https://www.mdpi.com/2072-6694/18/21/3480},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Real-World Eligibility for FLAURA, FLAURA2, and MARIPOSA in Patients with EGFR-Mutated Advanced NSCLC: A Retrospective Single-Center Study
AU - Silvia Marchesi
AU - Paolo Ambrosini
AU - Chiara Cavalli
AU - Rebecca Romanò
AU - Alessia Vendittelli
AU - Stefano Natangelo
AU - Giuseppe Nardo
AU - Margherita Piccinelli
AU - Daniele Lorenzini
AU - Marta Brambilla
AU - Laura Mazzeo
AU - Teresa Beninato
AU - Giulia Corrao
AU - Federica Perrone
AU - Rosa Maria Di Mauro
AU - Andra Diana Dumitrascu
AU - Claudia Proto
AU - Arsela Prelaj
AU - Monica Ganzinelli
AU - Filippo Guglielmo Maria De Braud
AU - Giuseppe Lo Russo
AU - Mario Occhipinti
PY - 2026
DA - 2026/10/28
JO - Cancers
DO - 10.3390/cancers18213480
UR - https://www.mdpi.com/2072-6694/18/21/3480
AB - Introduction: First-line treatment options for EGFR-mutated NSCLC have expanded beyond osimertinib monotherapy following the FLAURA2 and MARIPOSA trials, which demonstrated improved long-term outcomes with combination strategies, albeit with increased toxicities. Given that randomized controlled trials (RCTs) typically enroll highly selected patients (pts), evaluating the representativeness of these cohorts in real-world (RW) practice is essential to inform RCT applicability. Methods: We retrospectively identified patients with EGFR-mutated advanced NSCLC treated with first-line osimertinib at Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, between January 2019 and August 2025. Clinical characteristics were collected, and eligibility for FLAURA, FLAURA2, and MARIPOSA was assessed according to the respective trial criteria. For survival analyses, patients were classified as trial-eligible or trial-ineligible according to FLAURA eligibility criteria, as all patients received first-line osimertinib. Results: Overall, 135 pts were included in the analysis; median age was 67 years (IQR 57–76), 17% had ECOG PS 2, and 11% harbored uncommon EGFR mutations. Only 31 patients (23%) met eligibility criteria for all three trials, whereas 91 (67%) were ineligible for all. The most frequent exclusion criteria included symptomatic CNS disease or spinal cord compression, ECOG PS 2, and EGFR mutation assessment by cytology or liquid biopsy. Both real-world progression free survival (rwPFS) and overall survival (OS) were numerically longer in trial-eligible than trial-ineligible patients (20.1 vs. 18.2 months and 29.9 vs. 22.3 months, respectively). Patients with negative prognostic characteristics such as ECOG PS ≥ 2, uncommon EGFR mutations, and liver metastases had significantly shorter OS, while other predefined risk factors showed only numerical trends. Conclusions: A substantial proportion of patients treated with first-line osimertinib in routine practice would not have met the eligibility criteria of pivotal EGFR-mutated NSCLC trials. Trial-ineligible patients had numerically shorter survival, likely reflecting adverse baseline characteristics. These findings highlight the limitations of direct extrapolation of RCT results to real-world populations.
SN - 2072-6694
ER -